Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05743946 · ClinicalTrials.gov registry record · Phase 4
Trikafta for Patients With Non-cystic Fibrosis Bronchiectasis
A Phase 4 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 4
- Development phase
- 32
- Enrollment target
NCT05743946 is a Phase 4 study that has completed, run by Emory University. The registered enrollment target is 32 participants.
The verdict
NCT05743946, a Phase 4 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 32 participants
- Enrollment target
Study Summary
Study participants with non-cystic fibrosis bronchiectasis will be given Trikafta for four weeks. The researchers will monitor clinical endpoints, quality of life, and weight. Additionally, cutaneous punch biopsy material material or blood samples from participants who agree to do this optional test will be collected to test cellular response to Trikafta.
Interventions
- DRUG Trikafta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2023-04-18 |
| Est. Completion | 2025-12-23 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05743946
The ClinicalTrials.gov registry entry for NCT05743946 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Trikafta is the first listed.
NCT05743946 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05743946 about?
NCT05743946 is a clinical study titled "Trikafta for Patients With Non-cystic Fibrosis Bronchiectasis". Study participants with non-cystic fibrosis bronchiectasis will be given Trikafta for four weeks. The researchers will monitor clinical endpoints, quality of life, and weight. Additionally, cutaneous punch biopsy material material or blood samples from participants who agree to do this optional test...
What is the current status of trial NCT05743946?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 32 participants. The study started on 2023-04-18. Estimated completion is 2025-12-23.
What interventions are being tested in trial NCT05743946?
The interventions under investigation include: Trikafta (DRUG).
Who is sponsoring clinical trial NCT05743946?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.